Results 251 to 260 of about 70,621 (279)

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Lancet, The, 2010
Yung-Jue Bang, Andrea Feyereislova, Lin Shen   +2 more
exaly  

Pertuzumab/trastuzumab/trastuzumab-emtansine

Reactions Weekly, 2018
openaire   +1 more source

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

New England Journal of Medicine, 2012
Luca Gianni, Ian E Krop, Mark D Pegram
exaly  

Trastuzumab

Reactions Weekly, 2013
openaire   +2 more sources

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Lancet, The, 2010
Luca Gianni, Vladimir Semiglazov, Alexey Manikhas   +2 more
exaly  

Trastuzumab

Reactions Weekly, 2012
openaire   +2 more sources

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Lancet, The, 2017
David A Cameron, Evandro de Azambuja, Ian Smith   +2 more
exaly  

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Lancet, The, 2023
exaly  

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Lancet, The, 2013
Evandro de Azambuja, Christian Jackisch, David A Cameron   +2 more
exaly  

Trastuzumab

Reactions Weekly, 2010
openaire   +1 more source